A phase II study of O 6-benzylguanine and temozolomide in pediatric patients with recurrent or progressive high-grade gliomas and brainstem gliomas: A Pediatric Brain Tumor Consortium study

Journal of Neuro-Oncology

Volumn 106, Issue 3, 2012, Pages 643-649

  Warren, Katherine E ^a   Gururangan, Sri ^b   Geyer, J Russell ^c   McLendon, Roger E ^b   Poussaint, Tina Young ^d   Wallace, Dana ^e   Balis, Frank M ^f   Berg, Stacey L ^g   Packer, Roger J ^h   Goldman, Stewart ⁱ   Minturn, Jane E ^f   Pollack, Ian F ^j   Boyett, James M ^e   Kun, Larry E ^k  

^a NATIONAL CANCER INSTITUTE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c SEATTLE CHILDREN S HOSPITAL   (United States)

^d BOSTON CHILDREN S HOSPITAL   (United States)

^e Operations and Biostatistics Center for the Pediatric Brain Tumor Consortium   (United States)

^f CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^g TEXAS CHILDREN S CANCER CENTER   (United States)

^h CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

ⁱ CHILDREN'S MEMORIAL HOSPITAL   (United States)

^j CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^k ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

more..

Author keywords

AGT; Alkylating agent; Brainstem glioma; Glioma; MGMT; Pediatric; Resistance

Indexed keywords

6 O BENZYLGUANINE; KI 67 ANTIGEN; TEMOZOLOMIDE;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BONE MARROW SUPPRESSION; BRAIN STEM TUMOR; CANCER GRADING; CANCER GROWTH; CANCER SIZE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CLINICAL EVALUATION; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FLUSHING; GASTROINTESTINAL SYMPTOM; GLIOMA; HEADACHE; HUMAN; INFECTION; LEUKOPENIA; LYMPHOCYTOPENIA; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHASE 2 CLINICAL TRIAL; PRESCHOOL CHILD; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; SCHOOL CHILD; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; URINE RETENTION;

ADOLESCENT; ANTINEOPLASTIC AGENTS; BRAIN STEM NEOPLASMS; CHILD; CHILD, PRESCHOOL; DACARBAZINE; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; DRUG THERAPY, COMBINATION; FEMALE; GLIOMA; GUANINE; HUMANS; KAPLAN-MEIER ESTIMATE; KI-67 ANTIGEN; MALE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TUMOR SUPPRESSOR PROTEINS; YOUNG ADULT;

EID: 84857039925     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-011-0709-z     Document Type: Article

References (39)

1. Friedman H, Dolan M, Pegg A et al (1995) Activity of temozolomide in the treatment of central nervous system xenografts. Cancer Res 55: 2853-2857
2. Stupp R, Hegi M, Gilbert M, Chakravarti A (2007) Chemoradiotherapy in malignant glioma: Standard of care and future directions. J Clin Oncol 25: 4127-4136 (Pubitemid 47492957)
3. Yung A, Prados M, Yaya-Tur R et al (1999) Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. J Clin Oncol 17: 2762-2771 (Pubitemid 29415233)
4. Brada M, Hoang-Xuan K, Rampling R et al (2006) Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol 12: 259-266
5. Sankar A, Thomas D, Darling J (1999) Sensitivity of short-term cultures derived from human malignant glioma to the anti-cancer drug temozolomide. Anticancer Drugs 10: 179-185 (Pubitemid 29141304)
6. Stupp R, Dietrich P, Ostermann K et al (2002) Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 20: 1375-1382 (Pubitemid 34177445)
7. Chibbaro S, Benvenuti L, Caprio A et al (2004) Temozolomide as first-line agent in treating high-grade gliomas: phase II study. J Neurooncol 67: 77-81 (Pubitemid 38418252)
8. Lashford L, Thiesse P, Jouvet A et al (2002) Temozolomide in malignant gliomas of childhood: a United Kingdom Children's Cancer Study Group and French Society for Pediatric Oncology Intergroup Study. J Clin Oncol 20: 4684-4691 (Pubitemid 36025286)
9. Broniscer A, Iacono L, Chintagumpala M et al (2005) Role of temozolomide after radiotherapy for newly diagnosed diffuse brainstem glioma in children: results of a multiinstitutional study (SJHG-98). Cancer 103: 133-139 (Pubitemid 39665466)
10. Nicholson H, Kretschmar C, Krailo M et al (2007) Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group. Cancer 110: 1542-1550 (Pubitemid 47463069)
11. Cohen K, Pollack I, Zhou T et al (2011) Temozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology Group. Neuro Oncology 13: 317-323
12. Cohen K, Heideman R, Zhou T et al (2011) Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children's Oncology Group. Neuro Oncology 13: 410-416
13. 6-benzylguanine, and resistance to alkylators in pediatric primary brain tumor cell lines. Clin Cancer Res 11: 2747-2755 (Pubitemid 40569477)
14. Donson A, Addo-Yobo S, Handler M et al (2007) MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastomas. Pediatr Blood Cancer 48: 403-407 (Pubitemid 46340105)
15. Denny B, Wheelhouse R, Stevens M et al (1994) NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA. Biochemistry 33: 9045-9051 (Pubitemid 24272851)
16. Stevens M, Hickman J, Langdon S et al (1987) Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[ 5, 1-d]-1, 2, 3, 5-terazin-4 (3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res 47: 5846-5852 (Pubitemid 18018717)
17. 6- methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol 26: 4189-4199
18. 6-methylguanine. Oncogene 26: 186-197 (Pubitemid 46095730)
19. 6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol 16: 3851-3857 (Pubitemid 29001538)
20. 6-alkylguanine-DNA alkyltransferase which confer significant resistance of human glial tumor xenografts to treatment with 1, 3-bis (2-chloroethyl)-1-nitrosourea or temozolomide. Clin Cancer Res 7: 421-428 (Pubitemid 32183048)
21. Gerson S (2002) Clinical relevance of MGMT in the treatment of cancer. J Clin Oncol 20: 2388-2399 (Pubitemid 34441669)
22. Ishii D, Natsume A, Wakabayashi T et al (2007) Efficacy of temozolomide is correlated with 1p loss and methylation of the deoxyribonucleic acid repair gene MGMT in malignant gliomas. Neurol Med Chir (Tokyo) 47: 341-349 (Pubitemid 47328144)
23. 6- benzylguaninemediated enhancement of chemotherapy. Mol Cancer Ther 1: 943-948
24. 6-alkylguanine-DNA alkyltransferase activity to temozolomide and BCNU. Br J Cancer 73: 1049-1052
25. 6- benzylguanine and temozolomide administered daily for 5 days to pediatric patients with solid tumors. J Clin Oncol 23: 7646-7653 (Pubitemid 46291829)
26. 6- benzylguanine in children with brain tumors: a pediatric brain tumor consortium report. Clin Cancer Res 13: 6712-6718 (Pubitemid 350206808)
27. 6-alkylguanine-DNA-alkyltransferase in malignant glioma. Mol Cancer Ther 5: 2531-2539 (Pubitemid 44650917)
28. Rich J, Sathornsumetee S, Keir S et al (2005) ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors. Clin Cancer Res 11: 8145-8157 (Pubitemid 41698759)
29. Brandes A, Ermani M, Basso U et al (2002) Temozolomide in patients with glioblastoma at second relapse after first line nitrosourea-procarbazine failure: a phase II study. Oncology 63: 38-41 (Pubitemid 34977935)
30. 6-benzylguanine in adults with recurrenttemozolomide-resistant malignant glioma. J Clin Oncol 27: 1262-1267
31. 6-benzylguanine for patients with nitrosourearesistant recurrent or progressive malignant glioma. J Clin Oncol 20: 2277-2283 (Pubitemid 34441654)
32. 6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study. J Clin Oncol 24: 4746-4753 (Pubitemid 46630938)
33. Donson A, Addo-Yobo S, Handler M et al (2007) MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma. Pediatr Blood Cancer 48: 403-407 (Pubitemid 46340105)
34. Newlands E (1992) Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer 65: 287-291
35. Patel M, McCully C, Godwin K et al (2003) Plasma and cerebrospinal fluid pharmacokinetics of intravenous temozolomide in non-human primates. J Neurooncol 61: 203-207 (Pubitemid 36342297)
36. Panetta J, Kirstein M, Gajjar A et al (2003) Population pharmacokinetics of temozolomide and metabolites in infants and children with primary central nervous system tumors. Cancer Chemother Pharmacol 52: 435-441 (Pubitemid 37491631)
37. 6-methylguanine- DNA methyltransferase inhibition in the nonhuman primate. Cancer Res 55: 4604-4610
38. 6-benzylguanine for patients undergoing surgery for malignant glioma. J Clin Oncol 16: 3570-3575 (Pubitemid 28506770)
39. Karran P, Bignami M (1994) DNA damage tolerance, mismatch repair and genome instability. Bioessays 16: 833-839